Monoclonal antibodies against psoriasis

A drug, still under study by Johnson & Johnson shows positive effects that bode well against psoriasis , one of the most common forms of chronic dermatitis in the world. The news reported from a phase 3 study of Ustekinumab (CNTO 1275) shows a significant reduction, quantified around 75% (data obtained by measuring the affected skin area) of psoriasis after taking two doses of the drug in a period of 12 weeks. CNTO 1275 is an immunosuppressive drug developed with monoclonal antibodies, i.e. from a single immune cell and therefore monospecific. These products have the enormous advantage of being able to selectively interfere, at various levels and with different modes of action, in the immunological processes that trigger and sustain psoriasis because, as is by now known, both cells of the skin, such as keratocytes, and blood cells intended for immune defense, such as T lymphocytes.